Navigation Links
Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
Date:7/17/2008

ely 680 patients. To be eligible, patients must have a viral load greater than 5,000 copies/mL at screening and may not have taken any anti-HIV drugs prior to enrolling, as well as meet other screening criteria. The primary endpoint of the studies is to assess the proportion of patients with viral load < 50 copies/mL at week 48 on TMC278 vs. control (EFV). The studies will last for 104 weeks, which includes a four-week screening period, a 96-week treatment period and a four-week follow-up period.

Results from both of these studies will be submitted to the U.S. Food and Drug Administration (FDA) for consideration for approval of TMC278.

TMC278 is the third anti-HIV compound to be developed by Tibotec Pharmaceuticals. Tibotec Pharmaceuticals is also developing other investigational compounds for the treatment of hepatitis C and tuberculosis.

For additional information on inclusion and exclusion criteria for both of these studies, please see http://www.clinicaltrials.gov or email info@tibbe.jnj.com.

About Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Tibotec is a member of the Johnson & Johnson family of companies.

Forward Looking Statement

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Tibotec's expectations and projections. Risks and uncertaint
'/>"/>

SOURCE Tibotec Pharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Maine Natural Health Company Conducts Dental Clinical Trial
3. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
4. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
5. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
6. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
7. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
8. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
9. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
10. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
11. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- 4WEB Medical announces the formal launch of the ... on the market today at this weekend,s American ... Chicago .  The Osteotomy Truss System is a ... 74 size options included in one versatile set. Previously ... to 18 implant sizes, which limited a surgeon,s ability ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica US ... leading online community to help oncologists and other clinicians ... regarding the use of targeted therapies and immunotherapies, discusses ... and treatment.  Every September, Blood ... to raise awareness about blood cancers—helping to increase survival ...
(Date:9/19/2014)... , Sept. 19, 2014  Pressure BioSciences, ... announced it has received and approved all parts ... instruments and has begun to manufacture the new ... instrument will be ready for shipment by mid-October ... and released at a rate of about one ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
... a,division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today,that the ... pediatric,exclusivity for TOPAMAX(R) (topiramate), based on studies submitted ... to investigate the use of TOPAMAX,in pediatric patients ... seizures., In addition to granting pediatric exclusivity, ...
... There are a record 301,new medicines being ... released here today during a briefing that focused ... patients, their families,and society. Nationwide, mental illness affects ... the Pharmaceutical Research and Manufacturers,of America (PhRMA), featured ...
Cached Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4
(Date:9/20/2014)... (PRWEB) September 20, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continue to ... insurer has announced plans to end coverage for ... its website last month, Harrisburg, Pennsylvania-based Capital BlueCross ... 1, 2014. The insurer said its decision was ...
(Date:9/20/2014)... PITTSBURGH, PA (PRWEB) September 20, 2014 "As ... left in their tanks," said an inventor from Tamaqua, Pa. ... are mounted on the backs of their chairs. My invention ... She developed the Kam Oxygen Sensor to make it easier ... ensures that the user knows when the tank is low. ...
(Date:9/20/2014)... September 20, 2014 RBSEO Services, which ... marketing companies, has announced it provides an affordable website ... , This announcement would benefit those new and ... market but cannot afford to pay a big amount ... visibility of their websites in top search results for ...
(Date:9/20/2014)... MarijuanaDoctors.com recently returned to New ... PAIN Week conference that was held at the ... Las Vegas from September 2nd to September 6th. ... in the hopes of educating physicians in regards ... tool to treat chronic Pain, MarijuanaDoctors.com accomplished goals ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Are you ... because of problems with seasonal allergies or sinus congestion? ... much better alternative. , She conceived of Nose ... having a runny nose in public. Since it prevents ... promotes more sanitary conditions, particularly when cooking or working ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... institutions in Sweden are among the quickest to adopt a ... ( JoVE ), with over 35 percent of institutions ... this phenomenon is that Swedes are among the fastest people ... we are a very curious people and interested in new ...
... breakfast and lunch lose less weight compared to those who ... by researchers at Fred Hutchinson Cancer Research Center., The results ... a member of the Hutchinson Center,s Public Health Sciences Division ... the December issue of the Journal of the American ...
... risk of a second primary cancer of the same type, ... Canadian Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110167.pdf ... another type was only slightly elevated. Danish researchers looked ... 705 people) from 1980 to 2007 to determine whether ...
... Men may think about sex more often than women do, but ... needs, such as eating and sleep, more frequently than women do, ... men think about sex every seven seconds, which would amount to ... the study, the median number of young men,s thought about sex ...
... If cancer survivors develop a second cancer, it,s most likely ... researchers report. About 15 percent of cancer survivors worldwide ... the new report pointed out. In the study, investigators ... from 1980 to 2007 and found that about 10 percent ...
... use of recent experiences. Scientists from Ludwig-Maximilians-Universitt (LMU) ... test subjects to estimate distances in a virtual ... to approach the mean of all previously experienced ... to accurately predict the experimental findings using a ...
Cached Medicine News:Health News:Swedish people are quick to adopt JoVE, a video journal for biomedical sciences 2Health News:Mid-morning snacking may sabotage weight-loss efforts 2Health News:Mid-morning snacking may sabotage weight-loss efforts 3Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 2Health News:Risk of second cancer in cancer survivors mainly confined to the same cancer type as the first 3Health News:Study debunks stereotype that men think about sex all day long 2Health News:Study debunks stereotype that men think about sex all day long 3Health News:Study debunks stereotype that men think about sex all day long 4Health News:Second Cancer Often Same Type as the First, Study Finds 2Health News:When errors improve performance: Model describes how experiences influence our perception 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: